Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Cancer patients may be receiving higher doses and longer courses of expensive drugs than they need. Also, we see Moderna’s stock swing some thanks to profit-taking, and…
… I’ve taken to channeling Diogenes these days, choosing lentils over tyranny. I recommend, they’re most fibrous.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.